Duricef (cefadroxil) is a first-generation cephalosporin antibiotic indicated for the treatment of a wide range of bacterial infections. As an oral bactericidal agent, it works by inhibiting bacterial cell wall synthesis, leading to the eradication of susceptible microorganisms. This medication is commonly prescribed for skin and soft tissue infections, pharyngitis, tonsillitis, and urinary tract infections, offering a reliable option for both clinicians and patients seeking effective antimicrobial therapy with a well-established safety profile.

Features

• Active ingredient: Cefadroxil (monohydrate)
• Drug class: First-generation cephalosporin antibiotic
• Administration: Oral (capsules, tablets, suspension)
• Available strengths: 500 mg capsules, 1 g tablets, 250 mg/5 mL and 500 mg/5 mL oral suspension
• Prescription status: Rx-only medication
• Manufacturer: Various pharmaceutical companies under license
• Mechanism of action: Inhibition of bacterial cell wall synthesis

Benefits

• Demonstrates bactericidal activity against a broad spectrum of Gram-positive and some Gram-negative bacteria
• Provides convenient once or twice-daily dosing regimen depending on indication and severity
• Offers excellent oral bioavailability with consistent absorption regardless of food intake
• Shows proven efficacy in treating common community-acquired infections
• Features generally favorable tolerability profile with minimal gastrointestinal disturbance
• Presents cost-effective antibiotic option within the cephalosporin class

Common use

Duricef is primarily prescribed for the treatment of bacterial infections caused by susceptible strains of microorganisms. Common indications include streptococcal pharyngitis and tonsillitis, skin and skin structure infections such as cellulitis and impetigo, and urinary tract infections including cystitis. It may also be used off-label for certain dental infections and as surgical prophylaxis in specific cases. The medication is particularly valuable in outpatient settings where oral antibiotic therapy is appropriate for mild to moderate infections.

Dosage and direction

The dosage of Duricef varies based on the infection being treated, severity of infection, and patient factors including renal function. For adults with normal renal function, typical dosages range from 1 to 2 grams daily, administered either as a single dose or in divided doses every 12 hours. Pediatric dosing is based on body weight, typically 30 mg/kg/day in divided doses. For streptococcal pharyngitis, a 10-day course is recommended. Dosage adjustment is necessary in patients with impaired renal function (creatinine clearance <50 mL/min). The medication may be taken without regard to meals.

Precautions

Patients should complete the entire course of therapy even if symptoms improve to prevent development of resistant bacteria. Use with caution in patients with history of gastrointestinal disease, particularly colitis. May result in overgrowth of nonsusceptible organisms including fungi. Use with caution in patients with history of hypersensitivity reactions to penicillins or other beta-lactam antibiotics due to possible cross-reactivity. Prolonged use may result in superinfection. False-positive reactions for glucose in the urine may occur with Benedict’s or Fehling’s solutions but not with enzyme-based tests.

Contraindications

Duricef is contraindicated in patients with known hypersensitivity to cefadroxil, other cephalosporin antibiotics, or any component of the formulation. Should not be administered to patients who have experienced anaphylactic reactions to penicillins due to possible cross-sensitivity between beta-lactam antibiotics. Not recommended for patients with known phenylketonuria (certain formulations may contain phenylalanine).

Possible side effect

Common adverse reactions include gastrointestinal disturbances such as diarrhea (2-4%), nausea (1-2%), and abdominal pain. Less frequently reported effects include vomiting, dyspepsia, and glossitis. Hypersensitivity reactions may occur including rash, urticaria, and pruritus (1-2%). Rare but serious side effects include pseudomembranous colitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, and anaphylaxis. Transient elevations in liver enzymes, eosinophilia, and neutropenia have been reported. As with other antibiotics, Clostridium difficile-associated diarrhea may occur.

Drug interaction

Probenecid may decrease renal tubular secretion of cefadroxil, increasing and prolonging antibiotic blood levels. May reduce efficacy of oral contraceptives; additional contraceptive methods recommended during therapy. False-positive urine glucose tests may occur with certain methods. Laboratory test interactions may occur with direct Coombs’ test. No clinically significant interactions with warfarin have been established, but monitoring is advised when co-administered with anticoagulants.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed administration. Maintaining consistent antibiotic levels is important for therapeutic efficacy, so patients should strive to adhere to the prescribed dosing regimen.

Overdose

Symptoms of overdose may include nausea, vomiting, epigastric distress, and diarrhea. In cases of significant overdose, hemodialysis may aid in removal of the drug from the bloodstream. Management should be symptomatic and supportive. No specific antidote exists. Serum levels of cefadroxil can be measured if necessary. Patients should contact poison control or seek emergency medical attention if substantial overdose is suspected.

Storage

Store at controlled room temperature (20-25°C or 68-77°F). Keep container tightly closed. Protect from moisture and light. Oral suspension should be stored in refrigerator after reconstitution and discarded after 14 days. Keep out of reach of children. Do not use after expiration date printed on packaging. Do not freeze the medication.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Duricef is a prescription medication that should be used only under the supervision of a qualified healthcare professional. The prescribing physician should be consulted for diagnosis and treatment decisions. Individual patient response and appropriate dosing may vary based on specific clinical circumstances.

Reviews

Clinical studies have demonstrated Duricef’s efficacy with success rates exceeding 85-90% for indicated infections. Physicians appreciate its convenient dosing schedule and generally favorable side effect profile. Patients report satisfactory outcomes in treating common bacterial infections, with particular appreciation for the minimal gastrointestinal side effects compared to some other antibiotics. The medication has maintained its position in therapeutic guidelines for decades, affirming its established role in antimicrobial therapy.